Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan:90:107172.
doi: 10.1016/j.intimp.2020.107172. Epub 2020 Nov 3.

Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2

Shuangshi Wei  1 , Shengbao Duan  2 , Xiaomei Liu  1 , Hongmei Wang  1 , Shaohua Ding  1 , Yezhou Chen  1 , Jinsong Xie  1 , Jingjing Tian  1 , Nong Yu  3 , Pingju Ge  4 , Xinglin Zhang  4 , Xiaohong Chen  4 , Yong Li  5 , Qinglin Meng  6
Affiliations

Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2

Shuangshi Wei et al. Int Immunopharmacol. 2021 Jan.

Abstract

The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19.

Keywords: Chicken Egg Yolk Antibodies; IgY; Neutralizing agent; SARS-CoV-2; Spike protein variants.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Luminescence inhibition rate curve of the anti-(SARS-Cov-2) IgY (blue) and normal (control) IgY (red) from the pseudovirus neutralization assay. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2
Fig. 2
Competitive inhibition of the eight coronavirus spike protein mutants as determined by competitive ELISA.
See this image and copyright information in PMC

References

    1. Zhou P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. - PMC - PubMed
    1. Yan R., et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448. - PMC - PubMed
    1. Brouwer P.J.M., et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020 - PMC - PubMed
    1. Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–270. - PMC - PubMed
    1. Klemperer F. Uber natirliche Immunitat und ihre Verwertung fur die Immunisierungs-therapie. Arch. Expl. Pathol. Pharmakol. 1893;31:356–382.